全文获取类型
收费全文 | 805篇 |
免费 | 34篇 |
专业分类
耳鼻咽喉 | 5篇 |
儿科学 | 37篇 |
妇产科学 | 3篇 |
基础医学 | 73篇 |
口腔科学 | 48篇 |
临床医学 | 74篇 |
内科学 | 165篇 |
皮肤病学 | 56篇 |
神经病学 | 34篇 |
特种医学 | 22篇 |
外科学 | 100篇 |
综合类 | 25篇 |
预防医学 | 27篇 |
眼科学 | 37篇 |
药学 | 99篇 |
1篇 | |
中国医学 | 1篇 |
肿瘤学 | 32篇 |
出版年
2024年 | 1篇 |
2023年 | 7篇 |
2022年 | 35篇 |
2021年 | 53篇 |
2020年 | 12篇 |
2019年 | 18篇 |
2018年 | 21篇 |
2017年 | 18篇 |
2016年 | 28篇 |
2015年 | 28篇 |
2014年 | 39篇 |
2013年 | 46篇 |
2012年 | 76篇 |
2011年 | 81篇 |
2010年 | 30篇 |
2009年 | 25篇 |
2008年 | 41篇 |
2007年 | 51篇 |
2006年 | 44篇 |
2005年 | 26篇 |
2004年 | 20篇 |
2003年 | 28篇 |
2002年 | 43篇 |
2001年 | 20篇 |
2000年 | 12篇 |
1999年 | 9篇 |
1998年 | 5篇 |
1997年 | 5篇 |
1996年 | 1篇 |
1995年 | 1篇 |
1992年 | 1篇 |
1991年 | 2篇 |
1990年 | 2篇 |
1989年 | 2篇 |
1986年 | 1篇 |
1985年 | 1篇 |
1984年 | 1篇 |
1978年 | 1篇 |
1974年 | 1篇 |
1973年 | 1篇 |
1972年 | 2篇 |
排序方式: 共有839条查询结果,搜索用时 15 毫秒
1.
Bioavailability studies on guar gum-based three-layer matrix tablets of trimetazidine dihydrochloride in human volunteers. 总被引:1,自引:0,他引:1
Y S R Krishnaiah R S Karthikeyan P Bhaskar V Satyanarayana 《Journal of controlled release》2002,83(2):231-239
Guar gum-based three-layer matrix tablets of a highly water-soluble drug, trimetazidine dihydrochloride, were evaluated for their in vivo release in healthy volunteers in comparison with commercially available conventional immediate release tablets. Six healthy volunteers participated in the study and a two-way crossover design was followed. The plasma concentration of trimetazidine dihydrochloride was estimated by reverse-phase HPLC. The pharmacokinetic parameters were calculated from the plasma concentration of trimetazidine dihydrochloride versus time data. The delayed T(max), decreased C(max) and K(a), unaltered bioavailability, and prolonged t(1/2) and MRT indicated a slow and prolonged release of trimetazidine dihydrochloride from guar gum three-layer matrix tablets in comparison with the immediate release tablet dosage form. The guar gum three-layer matrix tablets of trimetazidine dihydrochloride may be useful in providing constant drug delivery with minimum fluctuations. 相似文献
2.
3.
4.
New approaches to preventing restenosis 总被引:1,自引:0,他引:1
Balram Bhargava Ganesan Karthikeyan Alexandre S Abizaid Roxana Mehran 《British medical journal》2003,327(7409):274-279
5.
S M Al-Saidan Y S R Krishnaiah V Satyanarayana P Bhaskar R S Karthikeyan 《European journal of pharmaceutics and biopharmaceutics》2004,58(3):697-703
The objective of the present study is to carry out pharmacokinetic evaluation of oral controlled release formulation (guar gum-based three-layer matrix tablets) containing highly soluble metoprolol tartrate as a model drug. Six healthy volunteers participated in the study, and a two-way crossover design was followed. The plasma concentration of metoprolol tartrate was estimated by reverse-phase HPLC. The pharmacokinetic parameters were calculated from the plasma concentration of metoprolol tartrate versus time data. The delayed T(max) lower C(max) decreased K(a) unaltered bioavailability and prolonged t(1/2) indicated a slow and prolonged release of metoprolol tartrate from guar gum three-layer matrix tablets in comparison with the immediate release tablet dosage form. The results of the study indicated that guar gum three-layer matrix tablets were able to provide oral controlled delivery of highly water-soluble drug such as metoprolol tartrate in humans. 相似文献
6.
Richard S P Huang Julie Y Tse Lukas Harries Ryon P Graf Douglas I Lin Karthikeyan Murugesan Matthew C Hiemenz Vamsi Parimi Tyler Janovitz Brennan Decker Eric Severson Mia A Levy Shakti H Ramkissoon Julia A Elvin Jeffrey S Ross Erik A Williams 《The oncologist》2022,27(8):655
BackgroundIn the current study, we examined the real-world prevalence of highly pigmented advanced melanomas (HPMel) and the clinicopathologic, genomic, and ICPI biomarker signatures of this class of tumors.Materials and MethodsOur case archive of clinical melanoma samples for which the ordering physician requested testing for both PD-L1 immunohistochemistry (IHC) and comprehensive genomic profiling (CGP) was screened for HPMel cases, as well as for non-pigmented or lightly pigmented advanced melanoma cases (LPMel).ResultsOf the 1268 consecutive melanoma biopsies in our archive that had been submitted for PD-L1 IHC, 13.0% (165/1268) were HPMel and 87.0% (1103/1268) were LPMel. In the HPMel cohort, we saw a significantly lower tumor mutational burden (TMB, median 8.8 mutations/Mb) than in the LPMel group (11.4 mut/Mb), although there was substantial overlap. In examining characteristic secondary genomic alterations (GA), we found that the frequencies of GA in TERTp, CDKN2A, TP53, and PTEN were significantly lower in the HPMel cases than in LPMel. A higher rate of GA in CTNNB1, APC, PRKAR1A, and KIT was identified in the HPMel cohort compared with LPMel.ConclusionsIn this study, we quantified the failure rates of melanoma samples for PD-L1 testing due to high melanin pigmentation and showed that CGP can be used in these patients to identify biomarkers that can guide treatment decisions for HPMel patients. Using this practical clinical definition for tumor pigmentation, our results indicate that HPMel are frequent at 13% of melanoma samples, and in general appear molecularly less developed, with a lower TMB and less frequent secondary GA of melanoma progression. 相似文献
7.
8.
9.
10.
Rajamani D Thiel S Vajda S Camacho CJ 《Proceedings of the National Academy of Sciences of the United States of America》2004,101(31):11287-11292
We show that the mechanism for molecular recognition requires one of the interacting proteins, usually the smaller of the two, to anchor a specific side chain in a structurally constrained binding groove of the other protein, providing a steric constraint that helps to stabilize a native-like bound intermediate. We identify the anchor residues in 39 protein-protein complexes and verify that, even in the absence of their interacting partners, the anchor side chains are found in conformations similar to those observed in the bound complex. These ready-made recognition motifs correspond to surface side chains that bury the largest solvent-accessible surface area after forming the complex (> or =100 A2). The existence of such anchors implies that binding pathways can avoid kinetically costly structural rearrangements at the core of the binding interface, allowing for a relatively smooth recognition process. Once anchors are docked, an induced fit process further contributes to forming the final high-affinity complex. This later stage involves flexible (solvent-exposed) side chains that latch to the encounter complex in the periphery of the binding pocket. Our results suggest that the evolutionary conservation of anchor side chains applies to the actual structure that these residues assume before the encounter complex and not just to their loci. Implications for protein docking are also discussed. 相似文献